<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05076877</url>
  </required_header>
  <id_info>
    <org_study_id>CR109080</org_study_id>
    <secondary_id>73841937NSC1008</secondary_id>
    <nct_id>NCT05076877</nct_id>
  </id_info>
  <brief_title>A Study of Lazertinib (JNJ-73841937) in Healthy Participants</brief_title>
  <official_title>A Phase 1, Open-label, Study in Healthy Participants to Evaluate the Effect of Steady State Concentrations of Lazertinib (JNJ-73841937) on the Single-dose Pharmacokinetics of Probe Substrates (Midazolam, Rosuvastatin, and Metformin)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of steady-state concentrations of&#xD;
      lazertinib on the single-dose pharmacokinetics (PK) of probe substrates (midazolam,&#xD;
      rosuvastatin, and metformin) in healthy adult participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Concentration of Probe Substrates (Midazolam, Rosuvastatin, and Metformin) Co-administered with Lazertinib (Day 13) as Test Versus Plasma Concentration of Probe Substrates Administered Alone (Day 1) as Reference</measure>
    <time_frame>Predose up to 12 hours postdose (Days 1 and 13)</time_frame>
    <description>Plasma samples will be analyzed to determine concentrations of midazolam and its metabolite 1-OH-midazolam, rosuvastatin, metformin, or lazertinib using a validated, specific, and sensitive method on Day 1 versus Day 13 as a part of drug-drug interaction (DDI) assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to 56 days</time_frame>
    <description>AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with AEs by Severity</measure>
    <time_frame>Up to 56 days</time_frame>
    <description>Number of participants with AEs by severity will be reported. AE severity is a clinical determination of the intensity of an AE and is assessed by using the standard grades as follows: Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening and Grade 5= death related to AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Changes in Laboratory Test Results</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Number of participants with change in clinical laboratory test results (including hematology and serum chemistry) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Abnormalities in 12-lead Electrocardiograms (ECGs)</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Number of participants with clinically significant abnormalities in ECGs will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Abnormalities in Vital Signs</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Number of participants with clinically significant abnormalities in vital signs (including temperature [oral], pulse rate, and blood pressure) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Abnormalities in Physical Examination</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Number of participants with clinically significant abnormalities in physical examination (including height and body weight) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Lazertinib at steady-state</measure>
    <time_frame>Predose on Day 7, 9, 11, 13, and 14</time_frame>
    <description>Plasma concentration of lazertinib at steady-state will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Lazertinib Following Repeat Dosing for 10 Days</measure>
    <time_frame>Day 14, 15, 16, 17, 21, and 28</time_frame>
    <description>Plasma concentration of lazertinib following repeat dosing for 10 days will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lazertinib + Probe Substrates of Midazolam, Rosuvastatin, and Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of probe substrates of midazolam, rosuvastatin, and metformin on Day 1 under fasted conditions followed by a single oral dose of lazertinib under fed conditions from Day 5 to Day 14 except Day 13 which is under fasted conditions and co-administered with probe substrates under fasted conditions on Day 13.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lazertinib</intervention_name>
    <description>Lazertinib tablets will be administered orally, alone or in combination with probe substrates.</description>
    <arm_group_label>Lazertinib + Probe Substrates of Midazolam, Rosuvastatin, and Metformin</arm_group_label>
    <other_name>JNJ-73841937</other_name>
    <other_name>YH25448</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Midazolam (cytochrome P450 3A4 [CYP3A4] substrate) will be administered orally as a syrup as a part of probe substrates.</description>
    <arm_group_label>Lazertinib + Probe Substrates of Midazolam, Rosuvastatin, and Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin (breast cancer resistant protein [BCRP] substrate) tablet will be administered orally as a part of probe substrates.</description>
    <arm_group_label>Lazertinib + Probe Substrates of Midazolam, Rosuvastatin, and Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin (organic cation transporter 1 [OCT1] substrate) will be administered orally as a syrup as a part of probe substrates.</description>
    <arm_group_label>Lazertinib + Probe Substrates of Midazolam, Rosuvastatin, and Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy on the basis of medical history at screening only, and physical examination,&#xD;
             vital signs, and 12-lead electrocardiogram (ECG) performed at screening and at&#xD;
             admission to the study center&#xD;
&#xD;
          -  Healthy on the basis of clinical laboratory tests performed at screening and at&#xD;
             admission to the study center.&#xD;
&#xD;
          -  A woman who is considered surgically sterile but not postmenopausal, must have a&#xD;
             negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) at&#xD;
             screening and a negative urine pregnancy test on Study Day 1. (exemptions: pregnancy&#xD;
             test not required in female participants with prior hysterectomy or prior bilateral&#xD;
             oophorectomy)&#xD;
&#xD;
          -  Male participants must agree to use an adequate contraception method as deemed&#xD;
             appropriate by the investigator&#xD;
&#xD;
          -  Non-smoker or not using tobacco containing products for at least 6 months before first&#xD;
             study drug administration and test negative for cotinine at screening and Study Day 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of malignancy within 5 years before screening (exceptions are squamous and&#xD;
             basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy,&#xD;
             that in the opinion of the investigator, with written concurrence with the sponsor's&#xD;
             medical monitor is considered cured with minimal risk of recurrence)&#xD;
&#xD;
          -  History of suspected or confirmed coronavirus disease 2019 within 4 weeks before&#xD;
             intake of study drug, or tests positive for severe acute respiratory syndrome&#xD;
             coronavirus 2 (SARS-CoV-2) at admission to the study site&#xD;
&#xD;
          -  Known allergies, hypersensitivity, or intolerance to lazertinib or its excipients or&#xD;
             probe substrates&#xD;
&#xD;
          -  Taken any disallowed therapies, concomitant therapy before the planned first dose of&#xD;
             study drug&#xD;
&#xD;
          -  Had major surgery, (example, requiring general anesthesia) within 8 weeks before&#xD;
             screening, or will not have fully recovered from surgery, or has surgery planned&#xD;
             during the time the participant is expected to participate in the study or within 4&#xD;
             weeks after the last dose of study drug administration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR109080</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 17, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Lazertinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

